Table 3. Intracerebral inoculation of transgenic mice that express human PrP with vCJD and with vCJD previously adapted in TgMet129 or TgMet/Val129 mice*.
| Isolates |
Mean survival time, d ±SD (no. PrPres-positive/inoculated animals) [reference]† | ||
|---|---|---|---|
| TgMet129 |
TgMet/Val129 |
TgVal129 |
|
| Hu-vCJD1 | 626 ±29 (6/6) [31] | >700‡ (3/3)§ | >700‡ (0/5) |
| Hu-vCJD1→TgMet129 | 650 ±60 (4/4) | >700‡ (5/5) | >700‡ (5/5) |
| Hu-vCJD2 | 545 ±146 (5/5) | >700‡ (5/5) | >700‡ (0/6)# |
| Hu-vCJD2→TgMet129 | 564 ±39 (4/4) | >700‡ (5/5) | >700‡ (2/2)¶ |
| Hu-vCJD2→TgMet/Val129 | 601 ±32 (5/5) | 651 ±17 (7/7) | >700‡ (7/7) |
| Ca-BSE2→TgMet129 | 614 ±87 (6/6) | >700‡ (4/4) | >700‡ (3/4) |
| Ca-BSE/Sh(ARQ)→TgMet129 | 534 ±55 (5/6) | >700‡ (5/6) | >700‡ (5/6) |
| Ca-BSE/Go→TgMet129 | 609 ±67 (5/5) | >700‡ (4/4) | >700‡ (6/6) |
*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met129, methionine; PrP, prion protein; PrPres, proteinase K–resistant PrP; sCJD, sporadic CJD; Val129, valine; vCJD, variant CJD. †Survival time is indicated for all mice scored positive for PrPres. ‡Animals were euthanized without clinical signs at 700 dpi. §Three additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for brain PrPres on WB. ¶Four additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for PrPres expression on Western blot. #Positive subclinical infection tested in Bo-Tg110 mice.